J B Chemicals & Pharmaceuticals — a brand-compounding machine, now being folded into Torrent

The Pulse

JB Pharma is one of India’s best-run mid-cap drug companies — a chronic-and-cardiac branded franchise wrapped around a genuinely world-class lozenge-manufacturing business, throwing off mid-20s% returns on capital with essentially no debt. But the standalone story is ending. Over FY26, Torrent Pharma bought control from private-equity owner KKR (₹25,689 crore equity valuation), became the 48.8% promoter in January 2026, and is now amalgamating JB into Torrent — 51 Torrent shares for every 100 JB shares, with the NCLT hearing due in June 2026 and the merger likely effective by around July. The most recent quarter (March 2026) was deliberately ugly: revenue fell 5% and reported profit halved as new management ripped out a low-margin business and re-set the books to fit the parent. Underneath the cleanup, the engine is intact — gross margin actually rose to ~70%. What you’re now looking at is a high-quality asset in the first months of being absorbed by a larger, more cost-disciplined owner.

The Business

JB makes and sells medicines, and it makes money in three quite different ways. The biggest and best is domestic branded formulations — roughly ₹2,460 crore in FY26, about 60% of the ₹4,148 crore total, growing 9% and ranked #22 in the Indian pharma market. The crown jewels are chronic therapies, especially cardiac: brands like Cilacar (and its line extensions), Nicardia, Azmarda for heart failure, and Razel for cholesterol. Chronic is now half the domestic book and grew 19% in FY26 against an industry chronic rate of 14%. These aren’t commodity generics — several hold dominant shares in their molecule (Nicardia ~93%, Metrogyl ~82%, Cilacar ~55%), the kind of entrenched physician trust that compounds quietly for years.

The genuinely distinctive asset is the second leg: lozenges. JB is one of the top five makers of medicated and herbal lozenges in the world, exporting to 40-plus countries from a single highly automated plant in Daman, and it does this as a contract manufacturer (CDMO) for the biggest names in consumer health — Kenvue, P&G, Reckitt, Innova. Think of it as the invisible factory behind cough-drop brands you’d recognise: not glamorous, but hard to replicate, sticky, and high-margin. This is ~₹445 crore of revenue and the closest thing JB has to a moat that a competitor can’t simply buy its way into.

The third leg, international formulations plus API (~₹1,150 crore + ~₹75 crore), is the weak one — branded generics sold through distributors in Russia, South Africa, the US and the Gulf, plus bulk drugs (JB is the world’s largest maker of diclofenac API). It’s lumpy, lower-margin, and management has been deliberately shrinking the worst of it (low-margin South African government tenders) to lift quality of earnings.

What ties it together — and what made KKR’s ownership so transformative — is a repeatable trick: buy an undermanaged brand and compound it. Sporlac (a probiotic) went from ₹70 crore at acquisition to over ₹145 crore in three years; Razel crossed ₹100 crore from ~₹60 crore; an in-licensed Novartis ophthalmology portfolio that had been flat for two years started growing double-digit within a year of JB taking it over. Under KKR the operating margin re-rated from the high-teens to a durable ~27%, sales doubled, and a ₹572 crore debt pile was paid down to almost nothing. That track record — high-quality brands plus a turnaround machine plus a world-class niche factory — is exactly what Torrent paid up for.

How Management Thinks

You’re really looking at two management teams a year apart. Through most of FY26, the calls were run by the KKR-era team led by CEO Nikhil Chopra — a values-forward operator who reeled off franchise numbers as evidence, openly admitted soft spots (he’d point out that the legacy acute brands Rantac and Metrogyl were flat even while reporting a good quarter), and explicitly invited investors to hold him to “the top percentile of our guidance.” Candid on the business, deliberately mute on the deal: through three calls his refrain was a repeated, almost mantra-like “business as usual at JB.”

By the May 2026 call, the cast had changed and so had the register. Torrent’s own people now sit on JB’s earnings call — Torrent’s MD Aman Mehta runs it, Torrent’s CFO Sudhir Menon fields the money questions and gives the closing remarks, Torrent’s international head speaks for that segment. Chopra and the KKR nominees are gone; the registered office has moved from Mumbai to Torrent’s home turf in Ahmedabad. The language shifted from founder-operator pride to corporate “scale, synergy, disciplined integration.” The clearest read on the new philosophy is capital allocation: the dividend payout jumped from 37% to 50% of profit in a single year, with a near-zero-debt, cash-rich balance sheet (₹1,200 crore net cash). This is a business now being run for efficiency and cash return, not empire-building — fitting, since it’s heading into a merger and no longer needs to hoard.

On credibility, the KKR team largely did what it said — the margin expansion and deleveraging were real and delivered. The new team’s first move was telling in a different way: rather than flatter the inherited numbers, they chose to take a visible hit immediately to clean house. That’s a credible signal, but it also means the reported figures for the next year will be noisy and below the underlying trend. The one place management is visibly guarded is headcount — repeatedly declining to say whether the combined ~2,500-strong sales force shrinks after the merger, while hinting plainly that it will.

Where It’s Going

The strategy from here is simple to state: India-led, brand-led, cost-disciplined. The thesis Torrent keeps returning to is that JB’s chronic and cardiac brands are powerful but under-distributed, and pushing them through Torrent’s wider field coverage is the prize — the “coverage gap” in cardiac is the single biggest revenue synergy. Procurement savings are “already positive from April,” and overlapping corporate functions get rationalised over time.

The near term, though, is a cleanup year, and it’s worth understanding why March 2026 looked so bad. Management deliberately (a) killed the low-margin trade-generics business (~7–8% of India sales), (b) aligned credit terms, inventory and distribution to Torrent’s stricter model, and (c) normalised channel inventory in export markets — taking ~₹40 crore of mostly one-off charges in a single quarter. Revenue fell 5%, reported profit dropped to ₹101 crore from ~₹200 crore, but gross margin climbed to ~70% from 66%. Think of it as a new owner taking a deep breath and absorbing the pain up front. Because trade generics will keep dragging the reported India number until it cycles out of the base (around Q4 FY27), the headline growth will understate the healthier branded business — which grew 8% even in the messy quarter and which management expects back to low-teens within a couple of quarters.

The real tensions to watch are honest ones. The lozenge CDMO business is demand-rich but execution-constrained — JB admits its product-development team was too lean to convert the order book, and Torrent will need to fix that. International remains soft, dogged by West Asia weakness and shipping constraints. Working capital quietly deteriorated (inventory days hit a decade-high). And there’s the structural fact that overrides everything: JB Pharma as a listed entity is on track to disappear into Torrent. The quality of the asset isn’t in doubt; the question is execution of an integration, and how much of the value created over the KKR years now accrues to Torrent’s shareholders rather than to a standalone JB.

The Four Checks

1. Quality and moat. A genuinely good business with a real moat in two of its three legs. The domestic branded franchise rests on entrenched physician trust — Nicardia holds ~93% of its molecule, Metrogyl ~82%, Cilacar ~55%, and chronic therapies, now half the domestic book, grew 19% in FY26 against an industry 14%. The lozenge CDMO is rarer still: one of the world’s top five medicated-lozenge makers, supplying Kenvue, P&G and Reckitt from a single automated plant — qualified, sticky, and hard for a competitor to replicate. The third leg, distributor-led international generics and commodity API, has no moat worth the name, and the franchise’s durability now depends on Torrent’s stewardship rather than the team that built it. Call it a strong moat in the core, contestable at the edges.

2. Returns on incremental capital and runway. The record is the central story of the financials: ROCE climbed from 11–14% in FY17–18 to a steady 25.4%, with ROE at 18.9% and borrowings of ₹4 crore — mid-20s returns with no leverage doing the lifting. The reinvestment trick — buy an undermanaged brand and compound it — demonstrably worked: Sporlac went from ₹70 crore to over ₹145 crore in three years, Razel crossed ₹100 crore, and the debt-funded FY22–23 acquisition build earned its keep, with profit up 7x in eleven years on 3.6x sales. The soft spot is runway: FY26 sales grew just 5.9%, the payout has risen to 50% (a signal that less is being redeployed), and the redeployment engine now belongs to Torrent — the standalone runway is, quite literally, a few months to merger.

3. Capital allocation for the stage. Close to textbook at each stage. Heavy, debt-funded brand acquisitions when incremental returns justified them (borrowings peaked at ₹572 crore in FY23), then a hard three-year deleverage to ₹4 crore while still growing, then dividends stepped up as reinvestment needs fell — payout of 34%, 37%, then ~50% in FY26 (₹22 per share, roughly ₹353 crore) from a business sitting on ~₹1,200 crore of net cash and heading into amalgamation, which is exactly when hoarding stops making sense. No buyback appears anywhere in the visible record, so that test can’t be marked. The quibbles are minor: working-capital days jumped from 87 to 126 and inventory hit a decade-high 192 days in the transition year, and future allocation is now Torrent’s call, not JB’s.

4. Price. Demanding. As of the June 2026 snapshot the stock trades at ₹2,234 — 49.9 times FY26 earnings, 8.65 times book, a 1% dividend yield, near the top of its 52-week range. That is a premium-compounder multiple on a year in which sales grew 5.9% and profit 7.4%, the slowest in years — even granting the deliberately ugly reset quarter and an underlying branded business growing ~11%. The price is also, in practice, no longer JB’s own: with the NCLT hearing due in June 2026 and the merger expected effective within a couple of months, the stock is essentially a 0.51 claim on Torrent shares, so the buyer is paying Torrent’s valuation for JB’s economics. Either way you frame it, the price assumes the synergy thesis works in full.

Sources

• Concall transcripts read: Q1 FY26 (call 31 Jul 2025), Q2 FY26 (Nov 2025), Q3 FY26 (Jan 2026), Q4 FY26 (call 12 May 2026) — all four quarters, full transcripts.
• Annual reports read: FY24, FY25, FY26 (high-signal sections + full reports where the trimmed sections were thin).
• Financial snapshot: screener.in (consolidated), fetched 2026-06-08, logged-out.
• Gaps / caveats: The auto-trimmed annual-report “sections” files for FY24 and FY25 (and partly FY26) were over-stripped of narrative; the digest agents fell back to the full report markdowns (same BSE-filed documents) — no web sourcing. A couple of verbal figures in the Jan-2026 transcript are OCR-garbled and were read against the stated margin guidance. No precise FY26 capex figure is disclosed in the report narrative (would need the cash-flow statement). The two dividend-payout readings (screener’s normalised 40.3% vs the FY26 P&L’s 50%) both point upward.
• Research dumps: vault/Sources/Earnings/J B Chemicals & Pharmaceuticals Ltd/ (not published).